In this systematic review and meta-analysis involving six RCTs and 2191 patients, we compared dexamethasone and immunomodulatory agent/proteasome inhibitor for both intervention and control groups and an anti-CD38 humanized IgG1-κ monoclonal antibody intervention for Relapsed or Refractory Multiple Myeloma. This evidence concerns the gene CD38 and plasma cell myeloma.